Oruka Therapeutics (ORKA) Profit After Tax (2010 - 2024)

Oruka Therapeutics' Profit After Tax history runs 15 years deep, the most recent figure standing at -$2.7 million for Q2 2024.

• On a quarterly basis, Profit After Tax fell 80.95% year-over-year to -$2.7 million in Q2 2024; TTM through Jun 2024 was -$7.2 million, a 13.69% decrease from a year earlier, with the FY2023 full-year figure at -$5.3 million, up 46.21% from the prior year.
• Profit After Tax eased to -$2.7 million in Q2 2024 per ORKA's latest filing, from -$2.0 million in the prior quarter.
• Across five years, Profit After Tax topped out at -$1.1 million in Q4 2023 and bottomed at -$5.7 million in Q4 2021.
• The 5-year median for Profit After Tax is -$2.2 million (2022), against an average of -$2.7 million.
• Across the five-year window, Profit After Tax tumbled 318.03% in 2020 and soared 79.32% in 2022, its largest moves.
• Year by year, Profit After Tax stood at -$5.1 million in 2020, then fell by 10.75% to -$5.7 million in 2021, then surged by 79.32% to -$1.2 million in 2022, then increased by 7.24% to -$1.1 million in 2023, then sank by 145.91% to -$2.7 million in 2024.
• Per Business Quant, the three latest ORKA Profit After Tax figures stand at -$2.7 million (Q2 2024), -$2.0 million (Q1 2024), and -$1.1 million (Q4 2023).